Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 20

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
The CacyBP/SIP protein is highly expressed in brain neurons, where it localizes in somata and in neuronal processes. The role of CacyBP/SIP is not clear at present but recently it has been suggested that the interaction between CacyBP/SIP and tubulin might be important for stability of microtubules in neuronal cells. Particularly, it was found that CacyBP/SIP changes its localization in an age-dependent way. Moreover, these changes in localization are similar to those observed for tau, a well known tubulin binding protein. Since it is known that changes in localization of tau during aging are similar to those observed in tauopaties (such as Alzheimer’s disease), in this work we examined the localization and possible role of CacyBP/SIP in mouse model of tauopathy (mice overexpressing the tau protein). We found that in young tauopathic mice CacyBP/SIP and tau are mainly present in neuronal somata whereas in wild type animals both proteins are localized in somata and in neuronal processes. Moreover, the tubulin staining pattern in transgenic mice was different than in wild animals. This might suggest that translocation of tau together with CacyBP/SIP affects stability of microtubules in neuronal cells. At present we examine whether posttranslational modifi cation(s) of CacyBP/SIP, such as phosphorylation, might be responsible for the observed translocation of CacyBP/SIP during tauopathy. This work was supported by statutory funds from the Nencki Institute of Experimental Biology.
The trophic effect of continuous intraventricular infusion of nerve growth factor (NGF) on morphology of the basal forebrain (BF) cholinergic neurons was tested in 4- and 28-month-old male Wistar rats. All studies were conducted using behaviorally uncharacterized animals from the same breeding colony. Immunohistochemical procedure for choline acetyltransferase (ChAT) and p75NTR receptor has been applied to identify cholinergic cells in the structures of basal forebrain (BF). Using a quantitative image analyzer, morphometric and densitometric parameters of ChAT- and p75NTR-positive cells were measured immediately after cessation of NGF infusion. In 28-month-old non-treated rats the number of intensively ChAT-positive cells in all forebrain structures was reduced by 50-70% as compared with young animals. The remaining ChAT-positive cells appeared shrunken and the neuropil staining was markedly reduced. In contrast, the same neurons when stained for p75NTR were numerous and distinctly visible with perfect morphology. Analysis of Nissl stained sections also showed that 28-month-old rats did not display significant losses of neuronal cell bodies. NGF restored the number of intensely stained ChAT-positive cells to about 90% of that for young controls and caused a significant increase in size of those cells in 28-month-old rats as compared with the control, age-matched group. NGF did not influence the morphology of p75NTR-positive neurons, which were well labeled, irrespective of treatment and age of the rats. In 4-month-old rats, NGF infusion decreased the intensity of both ChAT and p75NTR immunostaining. These data provide some evidence for preservation of BF cholinergic neurons from atrophy during aging and indicate that senile impairment of the cholinergic system in rats concerns decrease in ChAT-protein expression rather than an acute degeneration of neuronal cell bodies. Treatment with NGF resulted in restoration of cholinergic phenotype in the BF neurons of aged rats. However, the present study also rises issue of possible detrimental effects of NGF in young normal animals.
INTRODUCTION: Motor impairment is fundamental feature of Parkinson’s disease (PD). There are several reports on the beneficial effect of physical training on the PD symptoms reduction, however the mechanisms underlying this improvement are not known The selection of an appropriate animal model is crucial to demonstrate positive effect of physical effort on motor function, because even despite extensive loss of dopaminergic neurons the detection and quantification of motor impairment is difficult. AIM(S): The purpose of the study was to examine the efficacy of physical training in reversing the expected motor impairment in chronic MPTP mice model of parkinsonism. METHOD(S): C57BL/6 mice were treated for five weeks with 12,5 mg/kg MPTP in combination with 250 mg/kg probenecid. Mice were subdivided into: 1) control sedentary; 2) control trained (10 weeks); 3) MPTP sedentary (non-exercised with PD); 4) early trained MPTP (10 weeks: before, during, and after the induction of PD), and 5) late trained MPTP (10 weeks, started after the induction of PD). To assess motor performance rotarod, open field and inverted horizontal grid tests were performed before MPTP treatment, after the completion of intoxication and when the training was finished. RESULTS: MPTP did not impair motor function. We observed improvement of motor performance in rotarod and open field test in MPTP, early trained mice. Some enhancement of motor skills in rotarod test was observed also for MPTP non-exercised mice. In horizontal grid test the only parameter significantly influenced by MPTP treatment was the total number of touches and we did not observe the impact of physical training on the reduction of this parameter. CONCLUSIONS: We did not observe the impact of MPTP and physical training alone on motor performance in mice model of parkinsonism. However, there has been a certain improvement in some of the motor parameters in both groups of MPTP treated mice, which performed physical training. FINANCIAL SUPPORT: NCN grant 2014/15/B/ NZ4/05041
Tauopathies are a class of neurodegenerative diseases resulting from the pathological aggregation of tau protein in brain. The best known of these disorders is Alzheimer’s disease, where tau protein is deposited within neurons in the form of neurofibrillary tangles, which are formed by hyperphosphorylation of this microtubule-associated protein. Good animal model that mimic this form of age-related disease is still missing. Such a model should be characterized by: over expression, hyperphosphorylation and different cellular compartmentalization of tau in neurons, breakdown of cytoskeleton and malfunctioning of neuronal transport, and impairment of cognitive processes. We propose to develop such a model by local administration of full length tau directly into CA1 area of hippocampus in rats. Using specific pore-forming agent poly-APS we delivered tau protein through the membrane into the neurons where it is metabolized and may influence cognitive processes. Additional chronic administration of okadaic acid, a specific phosphatase inhibitor, caused tau hyperphosphorylation. Because tauopathies are age-related disorders, in our experiment we used several age-groups of animals to determine the age, in which we can provoke the morphological and cognitive impairments characteristic for tauopathy. Cognitive and neurodegenerative changes were examined with behavioral test and immunohistochemical techniques. Our data indicate that use of poly-APS enables for neuronal tau incorporation at selective brain site resulting in accelerated neurofibrillary tangle-like pathology. The major advance in the development of current tauopathy model is the determination of critical age at which it is possible to trigger morphological and cognitive impairments. This model mimics several pathologies observed in progressive dementia and could be successfully used in drug discovery to support therapeutic strategies.
Filamentous inclusions of tau protein are hallmarks of tauopathies including Alzheimer’s disease. Here a rat model for tauopathies was developed using pore-forming halitoxin Poly-APS. Tau protein was delivered through the membrane into the neurons where it is metabolized. Rats were injected with recombinant human Tau441 only (controls), Tau+Poly-APS (double) and Tau+PolyAPS+Okadaic Acid (triple). Cognitive and neurodegenerative changes were examined with Morrris water maze behavioral test and immunohistochemistry, respectively. Acquisition of the spatial reference memory was unaffected by administration of Tau or Tau+Poly-APS. However, enhanced phosphorylation of exogenously delivered tau with the triple infusion impaired learning. Hippocampal tau was visualized using antibodies against Tau441 and phosphorylated Tau-S404. The higher intensity of Tau441 immunostaining in double and triple groups suggests that exogenous tau is sequestered from the infusion solution into the cells. With respect to phospho-tau izoform we observed different cellular compartmentalization of P-Tau-S404 in double and triple treated rats. In double treated rats P-TauS401 was distributed both in the cell bodies and neuronal fi bers, while in triple group presence of OA caused redistribution of phospho-tau staining from neuronal processes to the perikaryon. This is similar to age-dependent tau redistribution between cellular compartments and could be a result of hyperphosphorylation.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 1 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.